Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Darlene Romashko
Observed name:
D. Romashko
Institution:
Stony Brook University
Observed institutions:
Cold Spring Harbor Laboratory,
Stony Brook University
OpenAlex ID:
A5025167139
A mouse model of Rubinstein-Taybi syndrome: Defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4
2003
·
Rusiko Bourtchouladze
, Regina Lidge
, et al.
·
Proceedings of the National Academy of Sciences
·
335
Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: Optimization of kinase selectivity and pharmacokinetics
2013
·
Keith R. Hornberger
, Xin Chen
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
30
Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
2022
·
Noboru Ishiyama
, Matthew O'Connor
, et al.
·
Cancer Research
·
27
Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1
2013
·
Keith R. Hornberger
, Dan M. Berger
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
24
Reversible Linkage of Two Distinct Small Molecule Inhibitors of Myc Generates a Dimeric Inhibitor with Improved Potency That Is Active in Myc Over-Expressing Cancer Cell Lines
2015
·
Jutta Wanner
, Darlene Romashko
, et al.
·
PLoS ONE
·
20
PDF
Identification of 5-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)thiophene-2-Carboxamides as Novel and Selective Monoamine Oxidase B Inhibitors Used to Improve Memory and Cognition
2017
·
Alan P. Kaplan
, Terence Keenan
, et al.
·
ACS Chemical Neuroscience
·
5
Preclinical efficacy of BDTX-4933, a brain penetrant MasterKey inhibitor targeting oncogenic BRAF Class I/II/III mutations
2022
·
P.Y. Ng
, Y.C. Han
, et al.
·
European Journal of Cancer
·
3
PDF
Abstract LB140: CNS penetrant, irreversible inhibitors potently inhibit the family of allosteric oncogenic EGFR mutants expressed in GBM and demonstrate efficacy in patient-derived xenograft models
2021
·
Matthew O'Connor
, Matt Lucas
, et al.
·
Cancer Research
·
2
EGFR Oncogenes Expressed In Glioblastoma Are Activated As Covalent Dimers And Paradoxically Stimulated By Erlotinib
2019
·
Matthew O’Connor
, Jie Zhang
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
2
PDF
Abstract A090: Preclinical efficacy of BDTX-4933, a brain-penetrant, orthosteric RAF inhibitor, targeting oncogenic RAF conformation shared by groups of BRAF and upstream driver mutations
2023
·
Yoon-Chi Han
, Pui Yee Ng
, et al.
·
Molecular Cancer Therapeutics
·
1
Data from Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
2023
·
Noboru Ishiyama
, Matthew O'Connor
, et al.
·
1
Abstract P246: Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers
2021
·
Etienne Dardenne
, Fernando Padilla
, et al.
·
Molecular Cancer Therapeutics
·
1
35MO Discovery and characterization of selective, FGFR1-sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers
2021
·
E. Dardenne
, F. Padilla
, et al.
·
Annals of Oncology
·
1
Supplementary Data from Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
2025
·
Noboru Ishiyama
, Matthew O'Connor
, et al.
Supplementary Table S3 from Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
2025
·
Noboru Ishiyama
, Matthew O'Connor
, et al.
Supplemental Materials from Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
2024
·
Noboru Ishiyama
, Matthew O'Connor
, et al.
Supplemental Materials from Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
2024
·
Noboru Ishiyama
, Matthew O'Connor
, et al.
Supplemental Materials from Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
2024
·
Noboru Ishiyama
, Matthew O'Connor
, et al.
Supplemental Materials from Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
2024
·
Noboru Ishiyama
, Matthew O'Connor
, et al.
Supplementary Data from Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
2023
·
Noboru Ishiyama
, Matthew O'Connor
, et al.
Data from Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
2023
·
Noboru Ishiyama
, Matthew O'Connor
, et al.
Supplementary Data from Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
2023
·
Noboru Ishiyama
, Matthew O'Connor
, et al.
Supplementary Table S3 from Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
2023
·
Noboru Ishiyama
, Matthew O'Connor
, et al.
Abstract P229: Pre-clinical evaluation of next-generation inhibitor targeting a wide spectrum of oncogenic BRAF dimers
2021
·
Yoon-Chi Han
, Pui Yee Ng
, et al.
·
Molecular Cancer Therapeutics
Abstract LB127: Prospective preclinical modeling to estimate clinical pharmacokinetics and doses of BDTX-189, an inhibitor of allosteric ErbB mutations in advanced solid malignancies
2021
·
Giorgio Ottaviani
, Matthew O'Connor
, et al.
·
Cancer Research
Show more works
View as search
Works count:
28
Citation count:
452
H-index:
5
I10-index:
5
Year
Topic
Type